Asgard Therapeutics awarded €2.5m EIC Accelerator grant to advance lead program AT-108 toward the clinic

 

  • European Innovation Council funding supports advancement of AT-108, Asgard’s first-in-class off-the-shelf cell reprogramming immunotherapy, toward First-in-Human clinical trial
  • Grant opens the door to up to €10 million in equity investment from the EIC Fund, the organisation’s venture capital investment arm
  • Award builds on recent progress with AT-108, including publication in Immunity and new translational biomarker data presented at SITC 2026

 

Lund, Sweden, 19 November 2026 – Asgard Therapeutics, a privately held biotech company pioneering in vivo direct cell reprogramming for cancer immunotherapy, today announces it has been awarded a €2.5 million European Innovation Council (EIC) Accelerator grant to advance its lead program, AT-108 into clinical development.

Read more…

© Optimum Strategic Communications.